null
ChEBI ID: 46919
| Member | Definition | Role |
|---|---|---|
| diethylcarbamazine | diethylcarbamazine | |
| PDGF receptor tyrosine kinase inhibitor III | An N-arylpiperazine that is piperazine in which the hydrogen attached to the nitrogen at position 1 is replaced by a (4-phenoxyphenyl)aminocarbonyl group, while the hydrogen attached to the nitrogen at position 4 is replaced by a 6,7-dimethoxyquinazolin-4-yl group. It is an inhibitor of tyrosine kinases FLT3, PDGFR and KIT. | PDGF receptor tyrosine kinase inhibitor III |
| tandutinib | An N-arylpiperazine that is piperazine in which the hydrogen attached to the nitrogen at position 1 is replaced by a 6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl group, while the hydrogen attached to the nitrogen at position 4 is replaced by a (p-isopropoxyphenyl)aminocarbonyl group. Tandutinib is an inhibitor of tyrosine kinases FLT3, PDGFR and KIT. | tandutinib |
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1,054 (53.64) | 18.7374 |
| 1990's | 299 (15.22) | 18.2507 |
| 2000's | 302 (15.37) | 29.6817 |
| 2010's | 236 (12.01) | 24.3611 |
| 2020's | 74 (3.77) | 2.80 |
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 199 (9.10%) | 5.53% |
| Reviews | 123 (5.62%) | 6.00% |
| Case Studies | 250 (11.43%) | 4.05% |
| Observational | 2 (0.09%) | 0.25% |
| Other | 1,614 (73.77%) | 84.16% |